Asabys Partners is a venture capital firm from Barcelona investing across the board in human healthcare. We are active in the health-tech and biopharma industries and aim to invest in Spain and abroad in highly innovative and transformative technologies. We are motivated by the idea of pushing the boundaries of science and medicine. We do this through the sourcing and financing of the most disruptive technologies, and through the collaboration with the best internal and external talents of our industry. We have an entrepreneurial spirit and seek to be involved in the building and management of our companies. Not just investors, we consider ourselves as partners and collaborators to our portfolio companies.

Origo Biopharma

Barcelona Ventures

Alantra

Asabys Partners

I just registered for BIO-Europe Spring on March 18–20, 2024. Join me at the premier springtime partnering event #BioEuropeSpring https://lnkd.in/dbBYdzbn . Informa Connect

We are very proud to announce the acquisition of our portfolio company Cara Care by Mahana, becoming a global leader in the digital treatment of digestive health and other chronic conditions. The combined company operates across the United States, Germany and the United Kingdom with both FDA-cleared and digital wellness programs for IBS and Tinnitus currently prescribed or offered by thousands of healthcare providers, and an exciting pipeline to reach the millions of patients suffering from IBD, Heartburn, Celiac Disease, Pruritus and Vulvodynia.
 
Asabys Partners, who invested in Cara Care back in 2019 through its fund Sabadell Asabys I, now becomes a shareholder of Mahana, also backed by prominent investors including JAZZ Venture Partners and Lux Capital.
 
Our Partner Guillem Masferrer comments: “Cara Care has become the first and only digital therapy specialized in digestive diseases that is reimbursed by the German health system. Germany is a pioneer country in the world in applying regulation to allow healthcare professionals to prescribe and reimburse digital therapies, as long as they prove a positive impact on patients. We are very proud to see how Cara Care has become a valid solution for patients who do not have therapeutic alternatives and are very excited about the opportunity to be able to bring these therapies to a global market with the help of Mahana."

Banco Sabadell  Alantra  European Investment Fund (EIF)
https://lnkd.in/dimDfmsy

Congratulations to our porforfolio company Gradient Denervation Technologies for their Early Feasibility Study in the US. Gradient has already enrolled the first patient suffering from pulmonary hypertension due to left-sided heart disease, which currently has no approved drug or device therapy.

 https://lnkd.in/g4Qd2UTF 

I just registered for BIO-Europe Spring on March 18–20, 2024. Join me at the premier springtime partnering event #BioEuropeSpring https://lnkd.in/dN6ie4xw . Informa Connect

Today is International Women’s Day and we wanted to highlight our amazing female team. At #Asabys, we are incredibly proud of our female colleagues, portfolio entrepreneurs and executives, of their achievements and contributions to developing novel solutions that solve unmet medical needs. 
#InspireInclusion since diverse teams advance faster, and better.

#internationalwomensday2024 #IWD2024 #InvestInWomen #womeninscience #WomenInVC #inspireinclusion 

Abingworth is a leading transatlantic life sciences investment firm. It invests in high-quality late-stage assets and provides the capital to meet the needs of companies in the life sciences sector.

Abingworth

Allox is a new center for genomic regulation spin-off launched with the support of Asabys. It focuses on genomic research and development in the healthcare sector.

Allox

Ona Therapeutics is a company supported by Asabys that specializes in developing innovative therapies for cancer and fibrotic diseases.

Ona Therapeutics

Origo Biopharma is an early-stage company backed by Asabys, focusing on biopharmaceutical research and development.

SpliceBio is an early-stage company supported by Asabys that focuses on innovative technologies in the healthcare sector, particularly in the field of bioelectronics.

SpliceBio

Asabys is a company that specializes in providing AI-driven solutions to enhance decision-making processes in various industries. The company leverages advanced analytics and machine learning algorithms to deliver insights and optimize operations for its clients.

Asabys

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 16, 2024 11:02 AM	b9fcd791
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	May 16, 2024 11:02 AM	a5bdcc19
translate crunchbase fundingrounds	general
peers	general
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:ASABYS

Asabys